Table 5.

Comparison of the response rate (percent) of patients who were TNF-α blockade-naïve versus TNF-α blockade failures at day 589 of the open-label long-term extension period

Patients achieving level (%)	Pedi 30	Pedi 50	Pedi 70	Pedi 90	Pedi 100	Inactive disease
Continuous abatacept, TNF-α blockade-naïve (n = 46)	89	87	76	57	39	46
Continuous abatacept, TNF-α blockade failure (n = 5)	100	100	60	60	40	20
Interrupted abatacept, TNF-α blockade-naïve (n = 41)	90	88	81*	46*	22*	24*
Interrupted abatacept, TNF-α blockade failure (n = 6)	67	50	33*	0*	0*	1*
Nonresponders in lead-in phase, TNF-α blockade-naïve (n = 17)	71	65	53*	24*	6	6
Nonresponders in lead-in phase, TNF-α blockade failure (n = 5)	80	60	20*	0*	0	0

Note:

^*Statistically significant difference.

Abbreviations: Pedi, American College of Rheumatology pediatric response rate; TNF-α, tumor necrosis factor alpha.